drugset / Trial / NCT03227016
Study in Patients With SCLC of Veliparib in Combination With Topotecan
NaSingle-groupOpen-labelTreatment
Summary
Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan
Timeline
- Start
- 2016-10
- Primary completion
- 2021-05
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 1.25 mg/m2 | — |
| Subject | Veliparib | Small molecule | — | — |